Page last updated: 2024-09-03

gefitinib and Empyema, Gall Bladder

gefitinib has been researched along with Empyema, Gall Bladder in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, KP; Shih, JY; Yu, CJ1

Other Studies

1 other study(ies) available for gefitinib and Empyema, Gall Bladder

ArticleYear
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine

2010